Nasdaq:US$15.56 (+0.04) | HKEX:HK$22.75 (-1.35) | AIM:£2.37 (+0.05)
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
13
HKEX
12
IN-HOUSE DISCOVERED
CLINICAL STAGE DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
NDA SUBMITTED IN THE US &
MAA SUBMITTED TO THE EMA
~40
CLINICAL TRIALS
AROUND THE GLOBE
4,600
PERSONNEL ACROSS
THE GROUP

OUR SCIENCE

Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.

R&D Philosophy Pipeline Products

Events, Circulars And Forms


J.P. Morgan Global China Summit - Healthcare Forum 2022-05-19 - 2022-05-20
Corporate Presentation for Investors 2022-03-04
2021 Full Year Financial Results 2022-03-03 - 2022-03-03